197 related articles for article (PubMed ID: 11163465)
1. Respiratory syncytial virus vaccines for otitis media.
Anderson LJ
Vaccine; 2000 Dec; 19 Suppl 1():S59-65. PubMed ID: 11163465
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus: reverse genetics and vaccine strategies.
Collins PL; Murphy BR
Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
[No Abstract] [Full Text] [Related]
3. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
[TBL] [Abstract][Full Text] [Related]
4. Biology of Infection and Disease Pathogenesis to Guide RSV Vaccine Development.
Boyoglu-Barnum S; Chirkova T; Anderson LJ
Front Immunol; 2019; 10():1675. PubMed ID: 31402910
[TBL] [Abstract][Full Text] [Related]
5. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
6. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.
Prince GA; Capiau C; Deschamps M; Fabry L; Garçon N; Gheysen D; Prieels JP; Thiry G; Van Opstal O; Porter DD
J Virol; 2000 Nov; 74(22):10287-92. PubMed ID: 11044072
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the development of subunit-based RSV vaccines.
Jaberolansar N; Toth I; Young PR; Skwarczynski M
Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
[TBL] [Abstract][Full Text] [Related]
9. Carriers for the delivery of a vaccine against respiratory syncytial virus.
Cranage M; Taylor G
Expert Opin Biol Ther; 2005 Jul; 5(7):939-52. PubMed ID: 16018739
[TBL] [Abstract][Full Text] [Related]
10. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
[TBL] [Abstract][Full Text] [Related]
11. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
[TBL] [Abstract][Full Text] [Related]
12. Respiratory Syncytial Virus-associated Acute Otitis Media in Infants and Children.
Phillips M; Finelli L; Saiman L; Wang C; Choi Y; Patel J
J Pediatric Infect Dis Soc; 2020 Nov; 9(5):544-550. PubMed ID: 32886769
[TBL] [Abstract][Full Text] [Related]
13. CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.
Harcourt JL; Brown MP; Anderson LJ; Tripp RA
Vaccine; 2003 Jun; 21(21-22):2964-79. PubMed ID: 12798640
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
15. Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1β Responses.
Russell RF; McDonald JU; Ivanova M; Zhong Z; Bukreyev A; Tregoning JS
J Virol; 2015 Sep; 89(17):8974-81. PubMed ID: 26085154
[TBL] [Abstract][Full Text] [Related]
16. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
17. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
[TBL] [Abstract][Full Text] [Related]
18. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
19. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
20. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
